February 24, 2017 10:57 PM ET


Company Overview of Palatin Technologies, Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysf...

Cedar Brook Corporate Center

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

22 Employees





Key Executives for Palatin Technologies, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $476.4K
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Age: 59
Total Annual Compensation: $435.2K
Compensation as of Fiscal Year 2016.

Palatin Technologies, Inc. Key Developments

Palatin Technologies, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2016

Palatin Technologies, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2016. For the quarter, the company's loss from operations was $9,440,875 compared to $12,628,424 a year ago. Net loss was $10,029,419 compared to $13,249,684 a year ago. Basic and diluted net loss per common share was $0.06 compared to $0.08 a year ago. There were no revenues recorded in the quarters ended December 31, 2016 and 2015. For the six months, the company's loss from operations was $21,876,305 compared to $24,426,075 a year ago. Net loss was $23,082,189 compared to $25,659,603 a year ago. Basic and diluted net loss per common share was $0.13 compared to $0.16 a year ago. The difference between the three months ended December 31, 2016 and 2015 was primarily attributable to the completion of the Phase 3 clinical trials of Rekynda program for HSDD.

Palatin Technologies, Inc Announces Closing of License Agreement with AMAG Pharmaceuticals, Inc. for North American Rights to Rekynda™

Palatin Technologies, Inc. announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. Palatin received an initial payment of $60,000,000 under the license agreement.

Palatin Technologies, Inc. to Report Q2, 2017 Results on Feb 09, 2017

Palatin Technologies, Inc. announced that they will report Q2, 2017 results at 11:00 AM, US Eastern Standard Time on Feb 09, 2017

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

January 9, 2017
Palatin Technologies, Inc., exclusive and non-exclusive licences related to bremelanotide

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Palatin Technologies, Inc., please visit www.palatin.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.